Your session is about to expire
← Back to Search
Helixor® M for Solid Tumors
Study Summary
This trial will study the effects of Helixor® M, a possible cancer treatment, in patients with advanced solid tumors. The goal is to find the maximum tolerated dose and to learn more about the safety and side effects of the drug.
- Solid Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has this type of study been conducted previously?
"To date, 225 clinical trials for Helixor® M have been initiated in 2395 cities and 74 nations. The first of these studies was sponsored by Genzyme (a Sanofi Company) back in 2007 with 698 participants; it culminated into a Phase 3 drug approval stage. In the 14 years since then, 297 further such investigations have taken place."
Who is the intended population for enrollment in this investigation?
"This clinical trial is seeking 58 participants with a malignancy aged between 18 and 100. To qualify, applicants must have not previously been exposed to mistletoe therapy, received first-line systemic treatment for metastatic disease that has either progressed or become refractory due to toxicities (other cases may be considered on an individual basis), demonstrate measurable lesions according to RECIST 1.1 criteria, have ECOG performance status of 0-2, life expectancy of greater than 3 months, WBC ≥3 000/mcL Absolute neutrophil count ≥1000/mcL Platelets ≥90 000/mcL Hemoglobin ≥9"
What medical issues does Helixor® M offer remediation for?
"Helixor® M is generally prescribed to those suffering from ovarian cancer, however it can also be utilized to address unresectable thymoma, locally advanced nonsquamous non-small cell lung cancer, and mesotheliomas."
Are geriatric patients being considered for this experiment?
"This medical trial is available to patients between the ages of 18-100, as per the defined eligibility requirements."
Are there current vacancies available for patients to join this clinical trial?
"It appears that clinicaltrials.gov does not currently list this trial as actively recruiting participants; the study was first published on March 1st 2017 and last edited on October 31st 2022. Although this particular study is inactive, there are 2810 other active studies looking for volunteers at present."
How many participants are involved in this medical experiment?
"This research program is no longer enrolling participants, with the last update to its listing occurring on October 31st 2022. If you are searching for other studies, there are 2585 active cancer-focused trials and 225 seeking patients for Helixor® M treatments available presently."
Is there a body of evidence attesting to the efficacy of Helixor® M?
"Presently, 225 active trials are being conducted to evaluate the efficacy of Helixor® M. Of these studies, 87 have progressed to Phase 3 and are taking place across 19466 different medical sites; most of which can be found in Winston-Salem, North carolina."
What are the likely risks associated with Helixor® M usage?
"With limited clinical data in regards to safety and efficacy, Helixor® M only received a score of 1."
Share this study with friends
Copy Link
Messenger